{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:01Z","timestamp":1794273901942,"version":"4.9.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1038\/s41433-020-01297-w","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T07:02:36Z","timestamp":1605942156000},"page":"2607-2612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression"],"prefix":"10.1038","volume":"35","author":[{"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6092-780X","authenticated-orcid":false,"given":"Lu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Mester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-2155","authenticated-orcid":false,"given":"Huasheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362:726\u201338.","journal-title":"N Engl J Med"},{"key":"1297_CR2","unstructured":"Ugradar S, Rootman DB. Case Series. Ophthal Plast Reconstr Surg 2018:1. http:\/\/insights.ovid.com\/crossref?an=00002341-900000000-98532. Accessed 27 Mar 2018."},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344.","journal-title":"Br J Ophthalmol"},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1507\/endocrj.EJ16-0165","volume":"63","author":"JW Kim","year":"2016","unstructured":"Kim JW, Woo YJ, Yoon JS. Is modified clinical activity score an accurate indicator of diplopia progression in Graves&rsquo; orbitopathy patients? Endocr J. 2016;63:1133\u201340. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27628269. Accessed 5 Jan 2018.","journal-title":"Endocr J"},{"key":"1297_CR5","unstructured":"Ugradar S, Rootman DB Case Series. Ophthal Plast Reconstr Surg 2018:1. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29465483. Accessed 28 Feb 2018."},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97:4454\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1297_CR7","first-page":"110","volume":"3","author":"L DPF","year":"2014","unstructured":"DPF L, S R, M B, et al. Low dose of rituximab for corticosteroid-resistant graves\u2019 orbitopathy. Eur Thyroid J. 2014;3:110. http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L71947247%0Ahttp:\/\/dx.doi.org\/10.1159\/000365244%0Ahttp:\/\/sfx.library.uu.nl\/utrecht?sid=EMBASE&issn=22350640&id=doi:10.1159%2F000365244&atitle=Low+dose+of+rituximab+for+corticosteroid","journal-title":"Eur Thyroid J"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6:287\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1297_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u2008\u00d7\u20082 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:299\u2013309.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181:4397\u2013405.","journal-title":"J Immunol"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","volume":"168","author":"J Pritchard","year":"2002","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942\u201350.","journal-title":"J Immunol"},{"key":"1297_CR12","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361.","journal-title":"N Engl J Med"},{"key":"1297_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352.","journal-title":"N Engl J Med"},{"key":"1297_CR14","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076\u201380.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01297-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01297-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T09:11:30Z","timestamp":1629364290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01297-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-01297-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RD\u2014Consultant Horizon Therapeutics, Immunovant Corporation. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}